What Do MoonLake's Latest Week 40 HS Results Really Mean for Investors

Key Takeaways

• MoonLake Immunotherapeutics (MLTX) recently announced positive Week 40 data for its lead asset, Sonelokimab, in Hidradenitis Suppurativa (HS), showing significant improvement over earlier Week 16 results.
• Despite initial investor skepticism regarding its competitive profile against UCB's Bimzelx, Sonelokimab's continued efficacy and favorable safety across multiple indications present a compelling long-term growth narrative.
• With a robust multi-indication pipeline, strong analyst consensus, and a clear regulatory path, MLTX is positioning itself as a significant player in the inflammatory disease market, though execution risks remain.

What Do MoonLake's Latest Week 40 HS Results Really Mean for Investors?

MoonLake Immunotherapeutics (NASDAQ: MLTX) recently delivered a crucial update on its lead investigational Nanobody therapy, Sonelokimab, announcing positive Week 40 results from its Phase 3 VELA clinical trials in Hidradenitis Suppurativa (HS) at the 2026 AAD Annual Meeting. This news, released on March 28, 2026, marks a significant turning point for the clinical-stage biopharmaceutical company, especially after the mixed reception of its Week 16 data in September 2025. The initial Week 16 readout, while showing statistical significance in VELA-1, was overshadowed by a higher-than-expected placebo response in VELA-2, leading to a substantial stock price correction.

However, the Week 40 data paints a more encouraging picture. MoonLake reported that clinical responses for patients treated with Sonelokimab continued to improve, with 62% of patients achieving the Hidradenitis Suppurativa Clinical Response (HiSCR) 75 endpoint. This is a considerable leap from the approximately 35% HiSCR75 response observed at Week 16 across the combined VELA program, demonstrating a sustained and deepening therapeutic effect over time. The HiSCR75 endpoint, which signifies at least a 75% reduction in abscess and inflammatory nodule count without an increase in abscess or draining tunnel count, represents a higher bar for clinical success compared to the HiSCR50 used in many other trials.

The company emphasized that Sonelokimab continues to show a favorable safety profile, consistent with previous studies, with no new safety signals detected. This consistent safety, combined with a convenient subcutaneous dosing regimen (every other week for induction, then monthly for maintenance), positions Sonelokimab as a potentially attractive option for patients suffering from this debilitating chronic inflammatory skin condition. The continued improvement in patient-reported outcomes, such as quality-of-life and pain scores, further underscores the drug's potential to address the significant unmet needs in the HS market, which is projected to grow from $1.84 billion in 2024 to $7.83 billion by 2034.

How Does Sonelokimab Stack Up Against the Competition, Particularly Bimzelx?

The competitive landscape for HS treatments is intensifying, with UCB’s Bimzelx (bimekizumab-bkz) often cited as the benchmark. Sonelokimab, an IL-17A and IL-17F inhibitor, has faced scrutiny regarding its ability to outperform or even match Bimzelx’s efficacy. Following the Week 16 results in September 2025, MoonLake’s stock saw a dramatic decline, dropping 88.77% from a close of $61.99 to an open of $6.96. This sharp reaction reflected investor concern that Sonelokimab's initial ~35% HiSCR75 response rate at Week 16 fell short of Bimzelx’s 64% HiSCR75 achieved at 96 weeks in its Phase 3 program.

However, direct comparisons between trials with different durations and patient populations can be misleading. The latest Week 40 data, showing a 62% HiSCR75 response, significantly narrows the perceived gap with Bimzelx, especially considering Sonelokimab achieved this in less than half the time. This sustained improvement beyond Week 16 suggests a more robust and durable response than initially feared. Sonelokimab's unique Nanobody single-domain antibody fragment technology, which inhibits both IL-17A and IL-17F and includes an albumin-binding domain, is hypothesized to facilitate deeper tissue access, a critical factor in treating complex inflammatory conditions like HS.

While Bimzelx has a head start with approvals in multiple indications, Sonelokimab's improving efficacy profile and favorable safety could carve out a significant market share. The convenience of its dosing schedule also offers a potential differentiator in patient adherence and preference. The initial market overreaction to the Week 16 data may have presented a buying opportunity for long-term investors who recognized the potential for continued improvement, a thesis now bolstered by the Week 40 results.

What Does MoonLake's Broader Pipeline Look Like Beyond HS?

MoonLake Immunotherapeutics is not a one-trick pony; its strategy revolves around establishing Sonelokimab as a multi-indication blockbuster. Beyond HS, the company is actively developing Sonelokimab across a portfolio of inflammatory diseases, showcasing a robust pipeline that could significantly de-risk its investment profile. This multi-disease R&D push is critical for a clinical-stage biotech, providing multiple shots on goal and reducing reliance on a single indication.

One promising area is Palmoplantar Pustulosis (PPP), a debilitating inflammatory skin condition. Sonelokimab received FDA Fast Track designation for PPP in February 2026, a crucial step that can accelerate its development and regulatory review. This designation was supported by positive Phase 2 LEDA trial data, which demonstrated a 64% reduction in mean Palmoplantar Psoriasis Area and Severity Index (ppPASI) score from baseline at Week 16, with 39% of patients achieving ppPASI75. These results highlight Sonelokimab's potential in another area of high unmet medical need.

Furthermore, Sonelokimab has shown strong efficacy in Axial Spondyloarthritis (axSpA). Positive topline results from the Phase 2 S-OLARIS trial were announced in February 2026, with 81% of patients achieving the Assessment of Spondyloarthritis International Society 40 (ASAS40) response criteria at Week 12. This compares favorably to Bimzelx's 47.7% ASAS40 response at Week 16, although cross-trial comparisons should be made with caution due to differences in trial design and patient populations. MoonLake is also progressing with Phase 3 IZAR trials in Psoriatic Arthritis (PsA), with primary endpoint readouts anticipated in Mid 2026 and H2 2026, and a Phase 3 VELA-TEEN trial in adolescent HS, with results expected in H1 2026. This broad pipeline underscores Sonelokimab's potential to challenge established therapies across several significant markets.

What Are the Key Financials and Analyst Sentiments for MLTX?

MoonLake Immunotherapeutics, currently trading at $17.32 with a market capitalization of $1.24 billion, is a clinical-stage company, meaning it does not yet generate significant revenue from product sales. Its financial health and future prospects are heavily tied to the successful development and commercialization of Sonelokimab. The company reported an EPS of -$0.92 in its last earnings call on February 25, 2026, which was in line with expectations. As a biotech, cash burn and clinical milestones are paramount.

Wall Street analysts maintain a largely bullish outlook on MLTX, with a consensus "Buy" rating from 14 analysts (out of 18 total, including 2 "Hold" and 2 "Sell"). The average analyst price target stands at $19.88, with a median of $20.00. However, the range is wide, from a low of $8.00 to a high of $35.00, reflecting the inherent volatility and event-driven nature of biotech investing. Notably, there have been recent upgrades, with Wolfe Research upgrading the stock from "Underperform" to "Outperform" on March 23, 2026, and Rothschild & Co upgrading from "Neutral" to "Buy" on March 19, 2026.

Looking ahead, analysts project MoonLake to generate $0.5 billion in revenue by FY 2029 and $0.9 billion by FY 2030, with an EPS of $2.74 by FY 2030. These forward estimates are contingent on regulatory approvals and successful commercialization, particularly for HS. The company's 52-week range of $5.95 to $62.75 highlights its extreme volatility, driven by clinical trial readouts and market sentiment. The recent positive Week 40 HS data, coupled with a strong multi-indication pipeline and favorable analyst sentiment, suggests a potential re-rating for MLTX as it moves closer to a Biologics License Application (BLA) submission for HS in H2 2026.

What Are the Risks and Opportunities for MLTX Investors?

Investing in clinical-stage biotechnology companies like MoonLake Immunotherapeutics inherently comes with significant risks and rewards. The primary opportunity lies in Sonelokimab's potential to become a best-in-class therapy across multiple inflammatory indications. The recent Week 40 HS data, demonstrating sustained and improving efficacy, strengthens the bull case for its market potential in HS, a market projected to reach nearly $8 billion by 2034. Success in additional indications like PPP, axSpA, and PsA could further expand Sonelokimab's peak sales potential, potentially making it a multi-billion-dollar asset. The "Nanobody" technology itself represents an innovative platform that could yield further drug candidates.

However, substantial risks persist. Regulatory approval is never guaranteed, and the path to submission for HS still involves discussions with agencies regarding statistical strategies, especially considering the higher placebo response in VELA-2 at Week 16. While the Week 40 data is encouraging, the final 52-week data, expected in Q2 2026, will be crucial. Competition from established players like UCB's Bimzelx and other emerging therapies could limit market penetration. Furthermore, the company's financial runway, while supported by its current market cap, will require careful management as it scales up manufacturing and commercialization efforts.

The biotech sector is notoriously sensitive to clinical trial outcomes, and any future setbacks in ongoing or planned trials could lead to significant stock price volatility. The company's beta of 1.24 indicates it is more volatile than the broader market. Investors should also consider the potential for dilution if MoonLake needs to raise additional capital to fund its extensive pipeline and commercial launch. Despite these risks, the improving clinical profile of Sonelokimab and the breadth of its pipeline offer a compelling risk-reward proposition for investors with a high tolerance for volatility and a long-term investment horizon.

MoonLake Immunotherapeutics is at a pivotal juncture, with Sonelokimab's Week 40 HS results providing a much-needed boost to its clinical narrative. The sustained efficacy, coupled with a broad and promising pipeline, positions MLTX for significant growth. While the path ahead involves navigating regulatory hurdles and intense competition, the potential for Sonelokimab to become a leading therapy across multiple inflammatory diseases makes MoonLake a compelling, albeit high-risk, investment to watch closely.

Want deeper research on any stock? Try Kavout Pro for AI-powered analysis, smart signals, and more. Already a member? Add credits to run more research.